The principal goal of this proposal is to identify the epigenetic and morphological effects of lead (Pb) exposure on the neural and neuronal differentiation of human embryonic stem cells (hESCs). Lead poisoning remains a significant health problem in the United States. Nationally, about 250,000 children aged 1-5 years have blood lead levels greater than 10 ?g of lead per deciliter of blood (current CDC action level). It s known that Pb exposure causes neurological problems in children, such as attention deficit disorder and loss of fine-motor coordination, but the mechanisms of Pb-induced neurotoxicity and the epigenetic basis for how Pb causes neurological deficits is not known. In humans, the brain starts forming at about three weeks after conception and continues to develop and mature well into the first years of life. Early brain development is a very sensitive time during which exposure to toxicants such as Pb can affect further brain development and maturation. In vitro differentiation of embryonic stem cells into neural precursor cells (NPCs) recapitulates the early stages of brain development in humans, giving one the unique opportunity to understand the effects of Pb on the formation of the human brain. The significance of the experiments proposed here is that they will allow one to get a unique look at the impact of Pb on the differentiation an the maturation of NPCs and at the potential changes in the global DNA methylation patterns associated with Pb exposure. These differences will reveal novel mechanisms of Pb neurotoxicity and will also establish a tentative epigenetic outline that can be used as an index for Pb exposure. NPC-derived neurons will be used to understand even subtle changes in genomic DNA CpG methylation status leading to the neurological alterations induced by Pb. Preliminary studies with NPCs derived from hESCs indicate that Pb is an epigenetic disruptor and causes rapid (within 24 hours) reprogramming of global DNA methylation levels. The hypothesis is that Pb causes changes in DNA methylation at specific CpG sites and that hESCs and NPCs will have changes in epigenetic signature that correlate with morphological, molecular, and functional changes in the hESC-derived neural precursors and neurons.
Three aims are proposed:
Aim 1. Determine the effects of chronic Pb exposure on the epigenetic profile of hESC- derived NPCs.
Aim 2. Examine the influence that Pb-mediated DNA methylation changes in candidate genes have on neuronal differentiation and gene expression. Outcomes: This project will allow one to understand how exposure to Pb leads to neural impairment and how the architecture of a DNA methylome leads to the neurotoxic effects of Pb. It will be a prototype study for the application of the emerging field of toxicogenomics to human brain development, where the concepts could be used to devise in vitro assays for a variety of teratogenic toxic agents for other types of cell lineages as well.

Public Health Relevance

Over 120 million people in the world have blood lead levels of greater than 10 micrograms per deciliter, which is considered the 'safe level'by the Centers for Disease Control. The investigators propose to use neurons derived from human embryonic stem cells in combination with sophisticated epigenetics and genomics techniques to understand the biological mechanism for the neurotoxicological effects of lead. In the five year period, the principal investigator will begin studies to see how lead affects DNA methylation and neuronal differentiation in human embryonic stem cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21ES021983-02
Application #
8539620
Study Section
Special Emphasis Panel (ZES1-TN-D (ST))
Program Officer
Tyson, Frederick L
Project Start
2012-09-03
Project End
2014-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
2
Fiscal Year
2013
Total Cost
$223,440
Indirect Cost
$76,440
Name
Wayne State University
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Ruden, Douglas M; Cingolani, Pablo E; Sen, Arko et al. (2015) Epigenetics as an answer to Darwin's ""special difficulty,"" Part 2: natural selection of metastable epialleles in honeybee castes. Front Genet 6:60
Sen, Arko; Heredia, Nicole; Senut, Marie-Claude et al. (2015) Early life lead exposure causes gender-specific changes in the DNA methylation profile of DNA extracted from dried blood spots. Epigenomics 7:379-93
Niu, Qi; Wang, Wei; Li, Qian et al. (2014) Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non-Small Cell Lung Cancer. Transl Oncol 7:303-8
Niu, Qi; Wang, Wei; Li, Qian et al. (2014) Intratumoral injection of cisplatin in various concentrations of ethanol for cisplatin-resistant lung tumors. Mol Clin Oncol 2:491-496
Senut, Marie-Claude; Sen, Arko; Cingolani, Pablo et al. (2014) Lead exposure disrupts global DNA methylation in human embryonic stem cells and alters their neuronal differentiation. Toxicol Sci 139:142-61
Antwih, Deborah A; Gabbara, Kristina M; Lancaster, Wayne D et al. (2013) Radiation-induced epigenetic DNA methylation modification of radiation-response pathways. Epigenetics 8:839-48
Niu, Qi; Wang, Wei; Li, Yong et al. (2013) Cisplatin in 5% Ethanol Eradicates Cisplatin-Resistant Lung Tumor by Killing Lung Cancer Side Population (SP) Cells and Non-SP Cells. Front Genet 4:163
Cingolani, Pablo; Cao, Xiaoyi; Khetani, Radhika S et al. (2013) Intronic non-CG DNA hydroxymethylation and alternative mRNA splicing in honey bees. BMC Genomics 14:666
Hirsch, Helmut V B; Lnenicka, Gregory; Possidente, Debra et al. (2012) Drosophila melanogaster as a model for lead neurotoxicology and toxicogenomics research. Front Genet 3:68
Lu, Xiangyi; Wang, Luan; Ruden, Douglas M (2012) Hsp90 inhibitors and the reduction of anti-cancer drug resistance by non-genetic and genetic mechanisms. Pharmaceuticals (Basel) 5:890-8

Showing the most recent 10 out of 21 publications